YTHDF1 and ovarian carcinoma: Encapsulation of YTHDF1 siRNA and docetaxel (DTX), a first-line chemotherapy drug for ovarian cancer, into MSC-derived MsEVs, resulted in significant tumor targeting and internal/lysosomal escape of YTHDF1 siRNA.